Zhou Wenqian, Huang Yonghe, Liu Jing, Liu Yiguo, Liu Yuqing, Yu Chen
Department of Nephrology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Key Laboratory of Adolescent Health Assessment and Exercise Intervention of Ministry of Education, College of Physical Education and Health, East China Normal University, Shanghai, China.
Int J Biol Markers. 2024 Jun;39(2):149-157. doi: 10.1177/03936155241236498. Epub 2024 Mar 6.
The correlation of the expression of ankyrin repeat domain (ANKRD) family members with renal cell carcinoma prognosis was investigated.
The GEPIA2, GEO2R, UALCAN, GDC, OncoLnc, TIMER, PanglaoDB, CancerSEA, and Tabula Muris databases were used. Twelve ANKRD family members were identified as having overexpressed renal cell carcinoma samples. The ANKRD13D was identified as a renal cell carcinoma-specific target by cross-referencing the multiple survival databases. To clarify the role of ANKRD13D, the expression of NAKRD13D was analyzed at the single-cell level.
ANKRD13D was mainly expressed in immune cells and positively correlated with Treg cell infiltration. The expression of ANKRD13D was also positively correlated with PDCD1, CTLA4, LAG3, TNFSF14, and ISG20. The overexpression of ANKRD13D in Treg was confirmed using reverse transcription-quantitative polymerase chain reaction. The structure of ANKRD13D was predicted using AlphaFold.
In conclusion, we identified ANKRD13D as a key immune regulator, and targeting ANKRD13D with immune checkpoints blockade may be a promoting strategy for renal cell carcinoma immunotherapy.
研究锚蛋白重复结构域（ANKRD）家族成员的表达与肾细胞癌预后的相关性。
使用GEPIA2、GEO2R、UALCAN、GDC、OncoLnc、TIMER、PanglaoDB、CancerSEA和Tabula Muris数据库。确定12个ANKRD家族成员在肾细胞癌样本中过表达。通过交叉引用多个生存数据库，将ANKRD13D确定为肾细胞癌特异性靶点。为阐明ANKRD13D的作用，在单细胞水平分析ANKRD13D的表达。
ANKRD13D主要在免疫细胞中表达，与调节性T细胞浸润呈正相关。ANKRD13D的表达还与程序性死亡受体1（PDCD1）、细胞毒性T淋巴细胞相关蛋白4（CTLA4）、淋巴细胞活化基因3（LAG3）、肿瘤坏死因子超家族成员14（TNFSF14）和干扰素刺激基因20（ISG20）呈正相关。使用逆转录定量聚合酶链反应证实了调节性T细胞中ANKRD13D的过表达。使用AlphaFold预测ANKRD13D的结构。
总之，我们将ANKRD13D确定为关键的免疫调节因子，用免疫检查点阻断靶向ANKRD13D可能是肾细胞癌免疫治疗的一种促进策略。
